Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/14/2010CA2742942A1 Combination of an oxidant and a photoactivator for the healing of wounds
05/14/2010CA2742910A1 Combinational therapy comprising dhodh inhibitor and methotrexate for treating autoimmune disease
05/14/2010CA2742897A1 Modulators of amyloid beta.
05/14/2010CA2742866A1 Lysosomotropic inhibitors of acid ceramidase
05/14/2010CA2742841A1 Treatment of restless leg syndrome and sleep disorders
05/14/2010CA2742821A1 Modulators of atp-binding cassette transporters
05/14/2010CA2742741A1 Substituted disulfonamides
05/14/2010CA2742725A1 Process for resolving zopiclone
05/14/2010CA2742718A1 Pharmaceutical aerosol composition
05/14/2010CA2742680A1 Pharmaceutical compositions for release control of methylphenidate
05/14/2010CA2742603A1 Formulations for the treatment of acute herpes zoster pain
05/14/2010CA2742602A1 Gamma secretase modulators
05/14/2010CA2742601A1 [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto
05/14/2010CA2742597A1 Modulation of toll-like receptor 4 expression by antisense oligonucleotides
05/14/2010CA2742596A1 Modulation of toll-like receptor 2 expression by antisense oligonucleotides
05/14/2010CA2742531A1 Modulation of toll-like receptor 5 expression by antisense oligonucleotides
05/14/2010CA2742515A1 Modulators of cxcr7
05/14/2010CA2742500A1 Gamma secretase modulators
05/14/2010CA2742435A1 New halogen-substituted compounds
05/14/2010CA2742356A1 Tiotropium bromide having a low degree of crystallinity
05/14/2010CA2742317A1 Gamma secretase modulators
05/14/2010CA2742281A1 Immunosuppression compound and treatment method
05/14/2010CA2742099A1 Heat sterilised injectable composition of hyaluronic acid or one of the salts thereof, polyols and lidocaine
05/14/2010CA2741842A1 Concentrated liquid diet
05/14/2010CA2741721A1 Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
05/14/2010CA2741660A1 Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
05/14/2010CA2741589A1 Pyrrolidines
05/14/2010CA2741537A1 Quinoxaline-based lxr modulators
05/14/2010CA2741500A1 Carbamate compound or salt thereof
05/14/2010CA2741332A1 (pyrrolidin-2-yl)phenyl derivatives for use in the treatment of pain
05/14/2010CA2741299A1 Isoindoline compounds for use in the treatment of cancer
05/14/2010CA2741050A1 Erbb-3 (her3)-selective combination therapy
05/14/2010CA2741047A1 Novel compounds as cannabinoid receptor ligands
05/14/2010CA2740794A1 Nilotinib hci crystalline forms
05/14/2010CA2740146A1 Immediate release dosage forms of sodium oxybate
05/14/2010CA2738785A1 Oxoazetidine derivatives, process for the preparation thereof and use thereof in human medicine and in cosmetics
05/14/2010CA2738749A1 Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics
05/14/2010CA2737393A1 Compositions and methods for minimizing or reversing agonist-induced desensitization
05/14/2010CA2727520A1 Nyasol and analogs thereof for the treatment of estrogen receptor beta-mediated diseases
05/13/2010US20100122362 Cells expressing alpha-synuclein and uses therefor
05/13/2010US20100121357 Tissue Penetrating Catheters having Integral Imaging Transducers and Their Methods of Use
05/13/2010US20100121255 Compound
05/13/2010US20100121254 Method and apparatus for skin treatment
05/13/2010US20100121253 Method and Apparatus of Low Strength Electric Field Network-Mediated Delivery of Drug, Gene, SI-RNA, SH-RNA Protein, Peptide, Antibody or Other Biomedical and Therapeutic Molecules and Reagents in Solid Organs
05/13/2010US20100121072 Candesartan cilexetil polymorphs
05/13/2010US20100121070 Methods for the synthesis of 1,2,4-oxadiazole benzoic acid compounds
05/13/2010US20100121061 Compounds capable of activating cholinergic receptors
05/13/2010US20100120921 Renin inhibitors for treatment of hypertension in patients with high sodium diet
05/13/2010US20100120920 N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
05/13/2010US20100120919 Methods for treating transthyretin amyloid diseases
05/13/2010US20100120918 Novel non-aqueous topical solution of diclofenac and process for preparing the same
05/13/2010US20100120917 Butylammonium modulators of fatty acid transport
05/13/2010US20100120916 Therapeutic agent and diagnostic agent for mitochondrial dysfunction brain diseases
05/13/2010US20100120914 Medicament for prophylactic and/or therapeutic treatment of hepatic steatosis or non-alcoholic steatohepatitis
05/13/2010US20100120912 Esters of capsaicinoids as dietary supplements
05/13/2010US20100120910 Cosmetic Compositions Comprising Esters Based on 2-Propylheptanol
05/13/2010US20100120909 Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
05/13/2010US20100120908 Eye drop preparation comprising latanoprost
05/13/2010US20100120907 Derivatives of amyris alcohols and eudesmol for treating cold sores and herpes
05/13/2010US20100120906 Modified release formulation and methods of use
05/13/2010US20100120904 Novel use of genistein
05/13/2010US20100120903 Anti-inflammatory agent
05/13/2010US20100120902 Standarized bioactive herbal extracts
05/13/2010US20100120901 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
05/13/2010US20100120900 Methods And Sequences To Preferentially Suppress Expression of Mutated Huntingtin
05/13/2010US20100120899 Tumor Repressor Genes in the Prevention of Cancer
05/13/2010US20100120898 MicroRNA Expression Signature for Predicting Survival and Metastases in Hepatocellular Carcinoma
05/13/2010US20100120896 Once-A-Day RNA-Polymerase inhibiting and elongation factor G (EF-G) inhibiting antibiotic pharmaceutical product, formulation thereof, and use thereof in treating infection caused by methicillin-resistant staphylococcus aureus
05/13/2010US20100120895 RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)
05/13/2010US20100120894 Intracellular DNA receptor
05/13/2010US20100120893 Compositions and Methods for Inhibiting Expression of Transthyretin
05/13/2010US20100120892 Methods and compositions for the inhibition of stat5 in prostate cancer cells
05/13/2010US20100120891 Use of a galectin-1-targeted rnai-based approach for the treatment of cancer
05/13/2010US20100120890 Ion channel modulating activity i
05/13/2010US20100120889 Skin care composition for accelerated production of collagen proteins and method of fabricating the same
05/13/2010US20100120888 Atorvastatin strontium salt and pharmaceutical composition comprising same
05/13/2010US20100120887 Sustained release formulation of melatonin
05/13/2010US20100120886 Aryl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
05/13/2010US20100120885 Novel Derivatives of Psammaplin A, A Method For Their Synthesis And Their Uses For The Prevention Or Treatment Of Cancer
05/13/2010US20100120883 Novel compounds
05/13/2010US20100120880 PROCESS TO PREPARE NEW SUBSITUTED 1H-BENZO[d]IMIDAZOL-2(3H)-ONES, NEW INTERMEDIATES AND THEIR USE AS BACE 1 INHIBITORS
05/13/2010US20100120877 Additional therapeutic use
05/13/2010US20100120876 Compounds, methods and formulations for the oral delivery of a glucagon-like peptide (glp-1) compound or a melanocortin-4 receptor (mc4) agonist peptide
05/13/2010US20100120875 Use of 4-[(4-thiazolyl)phenoxy]alkoxy-benzamidine derivatives for treatment of osteoporosis
05/13/2010US20100120874 Heterocyclic gamma secretase modulators
05/13/2010US20100120873 Prophylactic or therapeutic agent for age-related macular degeneration
05/13/2010US20100120872 Organic compounds and their uses
05/13/2010US20100120869 Compounds and methods for pkc theta inhibition
05/13/2010US20100120868 Process For Preparing Solid Dosage Forms of Rosiglitazone Maleate
05/13/2010US20100120867 Method of treatment
05/13/2010US20100120865 thiazol-2-yl-urea derivatives such as 3-{3-[4-Methyl-5-(4-pyrazol-1-yl-phenyl)-thiazol-2-yl]-ureido}-N-pyridin-3-yl-propionamide, used in the treatment of diseases ameloriated by inhibition of phosphatidylinositol 3-kinase, particularly inflammatory, allergic or autoimmune conditions
05/13/2010US20100120864 2-aminooxazolines as taar1 ligands
05/13/2010US20100120863 Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
05/13/2010US20100120862 Monocyclic compounds and their use as trpv1 ligands
05/13/2010US20100120861 Benzoic acid inhibitors of atp-sensitive potassium channels
05/13/2010US20100120860 Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
05/13/2010US20100120859 Novel case of renin inhibitors
05/13/2010US20100120858 Piperidine Derivatives
05/13/2010US20100120857 Use of tris-quaternary ammonium salts as pain modulating agents
05/13/2010US20100120856 Derivatives of the Aminated Hydroxyquinoline Class For Treating Cancers
1 ... 2268 2269 2270 2271 2272 2273 2274 2275 2276 2277 2278 2279 2280 2281 2282 2283 2284 2285 2286 2287 2288 ... 7860